Low-Dose Rate Irradiation Suppresses Expressions of Cell Cycle Relating Genes, Resulting in Modifications of Sensitivities to Anti-Cancer Drugs

1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

de González, A.B.; Darby, S. Risk of cancer from diagnostic X-Rays: Estimates for the UK and 14 other countries. Lancet 2004,

363, 345–351. https://doi.org/10.1016/S0140-6736(04)15433-0.

Samet, J.M.; Niwa, O. At the 75th Anniversary of the bombings of Hiroshima and Nagasaki, the radiation effects research foundation continues studies of the atomic bomb survivors and their children. Carcinogenesis 2020, 41, 1471–1472.

https://doi.org/10.1093/carcin/bgaa104.

Yeager, M.; Machiela, M.J.; Kothiyal, P.; Dean, M.; Bodelon, C.; Suman, S.; Wang, M.; Mirabello, L.; Nelson, C.W.; Zhou, W.; et

al. Lack of transgenerational effects of ionizing radiation exposure from the Chernobyl accident. Science 2021, 372, 725–729.

https://doi.org/10.1126/science.abg2365.

Morton, L.M.; Karyadi, D.M.; Stewart, C.; Bogdanova, T.I.; Dawson, E.T.; Steinberg, M.K.; Dai, J.; Hartley, S.W.; Schonfeld, S.J.;

Sampson, J.N.; et al. Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident. Science 2021,

372, eabg2538. https://doi.org/10.1126/science.abg2538.

Imano, N.; Nishibuchi, I.; Kawabata, E.; Kinugasa, Y.; Shi, L.; Sakai, C.; Ishida, M.; Sakane, H.; Akita, T.; Ishida, T.; et al. Evaluating individual radiosensitivity for the prediction of acute toxicities of chemoradiotherapy in esophageal cancer patients. Radiat. Res. 2020, 195, 244–252. https://doi.org/10.1667/RADE-20-00234.1.

Le Bourg, É. Hormesis, aging and longevity. Biochim. Biophys. Acta (BBA) Gen. Subj. 2009, 1790, 1030–1039.

https://doi.org/10.1016/j.bbagen.2009.01.004.

Rühm, W.; Azizova, T.V.; Bouffler, S.D.; Little, M.P.; Shore, R.E.; Walsh, L.; Woloschak, G.E. Dose-rate effects in radiation biology and radiation protection. Ann. ICRP 2016, 45, 262–279. https://doi.org/10.1177/0146645316629336.

Barsoumian, H.B.; Ramapriyan, R.; Younes, A.I.; Caetano, M.S.; Menon, H.; Comeaux, N.I.; Cushman, T.R.; Schoenhals, J.E.;

Cadena, A.P.; Reilly, T.P.; et al. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming

the inhibitory stroma. J. Immunother. Cancer 2020, 8, e000537. https://doi.org/10.1136/jitc-2020-000537.

Semenza, G.L. Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 2004, 5, 405–406. https://doi.org/10.1016/S15356108(04)00118-7.

Nakamura, H.; Bono, H.; Hiyama, K.; Kawamoto, T.; Kato, Y.; Nakanishi, T.; Nishiyama, M.; Hiyama, E.; Hirohashi, N.; Sueoka,

E.; et al. Differentiated embryo chondrocyte plays a crucial role in DNA damage response via transcriptional regulation under

hypoxic conditions. PLoS ONE 2018, 13, e0192136. https://doi.org/10.1371/journal.pone.0192136.

Wang, G.L.; Jiang, B.-H.; Rue, E.A.; Semenza, G.L. Hypoxia-inducible Factor 1 Is a Basic-Helix-Loop-Helix-PAS heterodimer

regulated by cellular 02 tension. Proc. Natl. Acad. Sci. USA 1995, 5, 5510–5514.

Forsythe, J.A.; Jiang, B.H.; Iyer, N.V.; Agani, F.; Leung, S.W.; Koos, R.D.; Semenza, G.L. Activation of vascular endothelial

growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. 1996, 16, 4604–4613.

https://doi.org/10.1128/MCB.16.9.4604.

Shimamoto, K.; Tanimoto, K.; Fukazawa, T.; Nakamura, H.; Kanai, A.; Bono, H.; Ono, H.; Eguchi, H.; Hirohashi, N. GLIS1, a

novel hypoxia-inducible transcription factor, promotes breast cancer cell motility via activation of WNT5A. Carcinogenesis 2020,

41, 1184–1194. https://doi.org/10.1093/carcin/bgaa010.

Wilson, W.R.; Hay, M.P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 2011, 11, 393–410. https://doi.org/10.1038/nrc3064.

Cairns, R.; Papandreou, I.; Denko, N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor

microenvironment. Mol. Cancer Res. 2006, 4, 61–70. https://doi.org/10.1158/1541-7786.MCR-06-0002.

Horsman, M.R.; Overgaard, J. The impact of hypoxia and its modification of the outcome of radiotherapy. J. Radiat. Res. 2016,

57, i90–i98. https://doi.org/10.1093/jrr/rrw007.

Khalesi, E.; Nakamura, H.; Lee, K.L.; Putra, A.C.; Fukazawa, T.; Kawahara, Y.; Makino, Y.; Poellinger, L.; Yuge, L.; Tanimoto,

K. The Krüppel-like Zinc finger transcription factor, GLI-Similar 1, is regulated by hypoxia-inducible factors via non-canonical

mechanisms. Biochem. Biophys. Res. Commun. 2013, 441, 499–506. https://doi.org/10.1016/j.bbrc.2013.10.083.

Nakamura, H.; Tanimoto, K.; Hiyama, K.; Yunokawa, M.; Kawamoto, T.; Kato, Y.; Yoshiga, K.; Poellinger, L.; Hiyama, E.;

Nishiyama, M. Human mismatch repair gene, MLH1, is transcriptionally repressed by the hypoxia-inducible transcription

factors, DEC1 and DEC2. Oncogene 2008, 27, 4200–4209. https://doi.org/10.1038/onc.2008.58.

Kanda, Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013, 48,

452–458. https://doi.org/10.1038/bmt.2012.244.

Weaver, B.A. How Taxol/Paclitaxel kills cancer cells. MBoC 2014, 25, 2677–2681. https://doi.org/10.1091/mbc.e14-04-0916.

Cells 2022, 11, 501

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

33.

34.

35.

36.

15 of 15

Wani, M.C.; Taylor, H.L.; Wall, M.E.; Coggon, P.; McPhail, A.T. Plant antitumor agents. VI. Isolation and structure of taxol, a

novel antileukemic and antitumor agent from Taxus Brevifolia. J. Am. Chem. Soc. 1971, 93, 2325–2327.

https://doi.org/10.1021/ja00738a045.

Cao, L.; Kawai, H.; Sasatani, M.; Iizuka, D.; Masuda, Y.; Inaba, T.; Suzuki, K.; Ootsuyama, A.; Umata, T.; Kamiya, K.; et al. A

novel ATM/TP53/P21-mediated checkpoint only activated by chronic γ-irradiation. PLoS ONE 2014, 9, e104279.

https://doi.org/10.1371/journal.pone.0104279.

Stewart-Ornstein, J.; Iwamoto, Y.; Miller, M.A.; Prytyskach, M.A.; Ferretti, S.; Holzer, P.; Kallen, J.; Furet, P.; Jambhekar, A.;

Forrester, W.C.; et al. P53 dynamics vary between tissues and are linked with radiation sensitivity. Nat. Commun. 2021, 12, 898.

https://doi.org/10.1038/s41467-021-21145-z.

Zhang, X.; Wang, F.; Wang, Z.; Yang, X.; Yu, H.; Si, S.; Lu, J.; Zhou, Z.; Lu, Q.; Wang, Z.; et al. ALKBH5 promotes the proliferation

of renal cell carcinoma by regulating AURKB expression in an M6A-dependent manner. Ann. Transl. Med. 2020, 8, 646–646.

https://doi.org/10.21037/atm-20-3079.

Chao, Y.; Shang, J.; Ji, W. ALKBH5-M6A-FOXM1 signaling axis promotes proliferation and invasion of lung adenocarcinoma

cells under intermittent hypoxia. Biochem. Biophys. Res. Commun. 2020, 521, 499–506. https://doi.org/10.1016/j.bbrc.2019.10.145.

Zhang, S.; Zhao, B.S.; Zhou, A.; Lin, K.; Zheng, S.; Lu, Z.; Chen, Y.; Sulman, E.P.; Xie, K.; Bögler, O.; et al. M 6 a demethylase

ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation

program. Cancer Cell 2017, 31, 591–606.e6. https://doi.org/10.1016/j.ccell.2017.02.013.

Xia, L.-M.; Huang, W.-J.; Wang, B.; Liu, M.; Zhang, Q.; Yan, W.; Zhu, Q.; Luo, M.; Zhou, Z.-Z.; Tian, D.-A. Transcriptional upregulation of FoxM1 in response to hypoxia is mediated by HIF-1. J. Cell. Biochem. 2009, 106, 247–256.

https://doi.org/10.1002/jcb.21996.

Valerie, K.; Povirk, L.F. Regulation and mechanisms of mammalian double-strand break repair. Oncogene 2003, 22, 5792–5812.

https://doi.org/10.1038/sj.onc.1206679.

Haber, J.E. Partners and pathways. Trends Genet. 2000, 16, 259–264. https://doi.org/10.1016/S0168-9525(00)02022-9.

Morrison, C. The controlling role of ATM in homologous recombinational Repair of DNA damage. EMBO J. 2000, 19, 463–471.

https://doi.org/10.1093/emboj/19.3.463.

Lee, S.E.; Mitchell, R.A.; Cheng, A.; Hendrickson, E.A. Evidence for DNA-PK-dependent and -independent DNA double-strand

break repair pathways in mammalian cells as a function of the cell cycle. Mol. Cell Biol. 1997, 17, 1425–1433.

https://doi.org/10.1128/MCB.17.3.1425.

Takata, M.; Sasaki, M.S.; Sonoda, E.; Morrison, C.; Hashimoto, M.; Utsumi, H.; Yamaguchi-Iwai, Y.; Shinohara, A.; Takeda, S.

Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping

roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J. 1998, 17, 5497–5508.

https://doi.org/10.1093/emboj/17.18.5497.

Al-Khafaji, A.S.; Davies, M.P.; Risk, J.M.; Marcus, M.W.; Koffa, M.; Gosney, J.R.; Shaw, R.J.; Field, J.K.; Liloglou, T. Aurora B

Expression modulates paclitaxel response in non-small cell lung cancer. Br. J. Cancer 2017, 116, 592–599.

https://doi.org/10.1038/bjc.2016.453.

Hoellein, A.; Pickhard, A.; von Keitz, F.; Schoeffmann, S.; Piontek, G.; Rudelius, M.; Baumgart, A.; Wagenpfeil, S.; Peschel, C.;

Dechow, T.; et al. Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck.

Oncotarget 2011, 2, 599–609. https://doi.org/10.18632/oncotarget.311.

Phadke, M.S.; Sini, P.; Smalley, K.S.M. The novel ATP-competitive MEK/Aurora Kinase inhibitor BI-847325 overcomes acquired

BRAF inhibitor resistance through suppression of Mcl-1 and MEK expression. Mol. Cancer Ther. 2015, 14, 1354–1364.

https://doi.org/10.1158/1535-7163.MCT-14-0832.

Carr, J.R.; Park, H.J.; Wang, Z.; Kiefer, M.M.; Raychaudhuri, P. FoxM1 Mediates resistance to Herceptin and paclitaxel. Cancer

Res. 2010, 70, 5054–5063. https://doi.org/10.1158/0008-5472.CAN-10-0545.

...